Send to

Choose Destination
FEMS Microbiol Rev. 2019 Feb 11. doi: 10.1093/femsre/fuz005. [Epub ahead of print]

Targeting malaria parasite invasion of red blood cells as an antimalarial strategy.

Author information

Research Centre for Infectious Diseases, School of Biological Sciences, University of Adelaide, Adelaide, Australia 5005.
Burnet Institute, Melbourne, Victoria, Australia 3004.
Deakin University, School of Medicine, Waurn Ponds, Geelong, Victoria, Australia 3216.
Department of Medicine, University of Melbourne, Australia.
Central Clinical School and Department of Microbiology, Monash University.
QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia 4006.


Plasmodium spp. parasites that cause malaria disease remain a significant global-health burden. With the spread of parasites resistant to artemisinin combination therapies in Southeast Asia, there is a growing need to develop new antimalarials with novel targets. Invasion of the red blood cell by Plasmodium merozoites is essential for parasite survival and proliferation, thus representing an attractive target for therapeutic development. Red blood cell invasion requires a co-ordinated series of protein/protein interactions, protease cleavage events, intracellular signals, organelle release and engagement of an actin-myosin motor, which provide many potential targets for drug development. As these steps occur in the bloodstream, they are directly susceptible and exposed to drugs. A number of invasion inhibitors against a diverse range of parasite proteins involved in these different processes of invasion have been identified, with several showing potential to be optimised for improved drug-like properties. In this review, we discuss red blood cell invasion as a drug target and highlight a number of approaches for developing antimalarials with invasion inhibitory activity to use in future combination therapies.


Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center